Clinical trials · New York
Major Depressive Episode clinical trials in New York
We’re tracking 37 recruiting major depressive episode studies with a site in New York — including Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT07065240RecruitingPhase 2
Study of SPT-300 for major depression with or without anxiety
This trial tests an experimental oral medication, SPT-300, for people with major depressive disorder, even if they also have mild anxiety. The goal is to see if it helps improve mood safely.
Brooklyn, New YorkAges 18–65 - NCT06793397RecruitingPhase 3
Study of an experimental psychedelic-like drug for depression (CYB003)
This study tests an investigational medication (CYB003) for people with major depression whose current antidepressant isn't working well enough. It looks at whether this treatment can help improve depression symptoms.
New York, New YorkAges 18–85 - NCT07111390Recruiting
Home-based light therapy for major depression
This trial tests whether a special light you can use at home can help treat major depression. It's a 60Hz light that you turn on and off repeatedly. If you're 24–65, have depression, and take a stable antidepressant, you may be able to participate.
New York, New YorkAges 24–65 - NCT07572526Recruiting
Brain Stimulation to Improve Sleep and Mood in Depression
This study tests a non-invasive brain stimulation technique called tDCS (transcranial direct current stimulation) to see if improving sleep can help reduce depression symptoms. You'll do short stimulation sessions at home and track your sleep and mood.
New York, New YorkAges 18–65 - NCT07621237RecruitingPhase 2
TNX-102 SL for Major Depressive Disorder
This study tests whether a new medication called TNX-102 SL can reduce depression symptoms better than a placebo (inactive pill). You'll take the medication daily and have regular check-ins to see how you're doing.
New York, New YorkAges 18 years+ - NCT06775379RecruitingPhase 3
Azetukalner vs. placebo for major depression
This trial tests an investigational medication called Azetukalner against a placebo to see if it helps reduce symptoms of major depressive disorder. You may qualify if you are currently in a depressive episode that started in adulthood and have not tried or failed only a few antidepressants.
Brooklyn, New YorkAges 18–74 - NCT05850689RecruitingPhase 3
Lumateperone add-on for major depression that didn’t improve
This study tests whether adding lumateperone to an antidepressant helps adults with major depressive disorder (MDD) who haven’t improved enough after trying at least two different antidepressants. It may help reduce depressive symptoms more than antidepressants alone.
Brooklyn, New YorkAges 18–65 - NCT06547489RecruitingPhase 2
Testing zelquistinel for major depression
This study tests whether zelquistinel, an investigational drug, can reduce symptoms of major depressive disorder (a type of clinical depression). It is for people who are currently experiencing a moderate to severe depressive episode and are not taking other antidepressants.
Cedarhurst, New YorkAges 18–64 - NCT06592833RecruitingPhase 2
Psilocybin with or without pimavanserin for depression
This study tests whether combining psilocybin (a psychedelic substance) with pimavanserin (a medication that may help reduce side effects) works better than psilocybin alone for treating major depressive disorder. It may help people who have not responded well to other treatments.
New York, New YorkAges 21–80 - NCT07115329RecruitingPhase 2
Testing Zelquistinel for major depression
This study tests a new oral medication called Zelquistinel (taken as a tablet) against a placebo for treating major depressive disorder. Researchers want to see if it can reduce depression symptoms, especially when other antidepressants haven't been tried or haven't worked.
Cedarhurst, New YorkAges 18–64 - NCT07276997RecruitingPhase 2
Study of Icalcaprant for major depressive disorder
This trial tests an oral medication called icalcaprant for adults with major depressive disorder (MDD). It aims to see if the drug can reduce depression symptoms and what side effects may occur.
New York, New YorkAges 18–65 - NCT07284667RecruitingPhase 2
A new medicine for depression that hasn't improved with other treatments
This trial tests a new medicine called ACP-211 in adults with major depression who have not gotten enough relief from at least two previous antidepressants. The goal is to see if it can help when other treatments have not worked well.
Brooklyn, New YorkAges 18–65 - NCT06911112RecruitingPhase 3
A new pill for depression when current treatment isn't working well enough
This trial tests an investigational medication (NBI-1065845) added to your current antidepressant to see if it can improve depressive symptoms. It is for people with moderate to severe depression who have not fully responded to their current antidepressant.
New York, New YorkAges 18 years+ - NCT06963021RecruitingPhase 3
Study of NBI-1065845 for depression that hasn't fully responded to treatment
This trial tests an investigational drug called NBI-1065845 added to your current antidepressant. It is for people with moderate to severe depression or persistent depressive disorder who have not improved enough with oral antidepressants alone.
Cedarhurst, New YorkAges 18 years+ - NCT07592689RecruitingPhase 3
DT120 Treatment for Major Depression
This study tests whether a new medication called DT120 can help people with moderate-to-severe depression feel better. You'd take the medication for several weeks while doctors track your mood and symptoms.
New York, New YorkAges 18–74 - NCT07573176RecruitingPhase 3
Seltorexant for Depression in Adults and Older Adults
This study tests a new medication called seltorexant as a standalone treatment for major depression. The trial is for adults and older adults who have depression that hasn't improved with other antidepressants or who haven't tried them yet.
Brooklyn, New YorkAges 18–74 - NCT06966401RecruitingPhase 3
Long-term safety study of a new depression treatment
This study tests a new oral medication (NBI-1065845) added to your current antidepressant to see if it's safe and tolerable over a long period for people with depression that hasn't fully responded to treatment.
Cedarhurst, New YorkAges 18 years+ - NCT07196501RecruitingPhase 3
Study of a new add-on treatment for depression maintenance
This trial tests a new medication (NBI-1065845) added to your current antidepressant to see if it helps maintain improvement in depression. It is for people whose depression hasn't fully responded to their current oral antidepressant.
Glen Oaks, New YorkAges 18 years+ - NCT05757791RecruitingPhase 2
Testing an SGLT2 diabetes drug for depression
This Phase 2 trial tests whether an SGLT2 medicine (like empagliflozin) can reduce symptoms of major depression. It may help people with moderate-to-severe depression who are otherwise eligible for the study.
New York, New YorkAges 18–65 - NCT06633016RecruitingPhase 2
ABX-002 for major depression (add-on treatment)
This trial tests a new medication called ABX-002 as an add-on to your current antidepressant. It's for people with moderate to severe depression who haven't gotten enough help from their current antidepressant alone.
Brooklyn, New YorkAges 18–65 - NCT06786624RecruitingPhase 3
Testing a new drug for depression that hasn't fully responded to treatment
This trial tests a new medication called NBI-1065845 added to your current antidepressant for people with depression that hasn't fully responded to treatment. It aims to see if this combination can better improve your symptoms.
Mount Kisco, New YorkAges 18 years+ - NCT06835855Recruiting
Does mother’s depression affect baby’s attention to emotions?
This study looks at how babies of mothers with depression pay attention to emotional faces. Researchers want to learn if these babies show different patterns of attention to happy or sad cues, which could help understand early development.
Binghamton, New YorkAges 6 months+ - NCT07076407RecruitingPhase 3
Testing a new antidepressant pill for depression
This study tests an experimental oral pill called azetukalner against a placebo to see if it safely reduces symptoms of major depressive disorder. It is for adults who are currently in a depressive episode lasting 6 weeks to 2 years and have not already tried multiple antidepressants that failed.
Mount Kisco, New YorkAges 18–74 - NCT04041479RecruitingPhase 3
Brain-scan guided rTMS for treatment-resistant depression
This trial tests whether using brain-related “biomarkers” from your scans to guide rTMS can improve depression that hasn’t responded to at least one antidepressant. It may help by targeting brain circuits linked to depression more precisely.
New York, New YorkAges 22–65
Major Depressive Episode trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting major depressive episode studies listed above.
- Neurocrine Clinical Site · 5 studies
- IMA Clinical Research Manhattan · 4 studies
- NYU Langone Health · 4 studies
- Integrative Clinical Trials · 3 studies
- Manhattan Behavioral Medicine · 3 studies
- Bioscience Research · 2 studies
- Fieve Clinical Research, Inc · 2 studies
- Neurobehavioral Research Inc · 2 studies
What taking part in a major depressive episode study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there major depressive episode clinical trials in New York?
- Yes. We're currently tracking 37 recruiting major depressive episode studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a major depressive episode study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a major depressive episode trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New major depressive episode studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.